| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 39.88 M USD | 22.24 M USD | 18.82 M USD | -5.15 M USD | -2.58 M USD | 12.37 M USD | 15.83 M USD | 9.88 M USD | 10.80 M USD | 19.72 M USD | 11.44 M USD | 8.12 M USD |
| Depreciation & Amortization | 22.46 M USD | 24.20 M USD | 23.08 M USD | 22.44 M USD | 23.98 M USD | 20.71 M USD | 18.32 M USD | 18.09 M USD | 9.74 M USD | 8.38 M USD | 5.86 M USD | 6.03 M USD |
| Stock-Based Compensation | 24.39 M USD | 14.24 M USD | 14.42 M USD | 12.34 M USD | 10.71 M USD | 6.91 M USD | 8.80 M USD | 6.33 M USD | 6.92 M USD | 6.33 M USD | 5.09 M USD | 3.44 M USD |
| Capital Expenditures | 39.04 M USD | 11.19 M USD | 7.43 M USD | 9.02 M USD | 13.09 M USD | 7.33 M USD | 8.07 M USD | 5.79 M USD | 6.63 M USD | 6.20 M USD | 3.49 M USD | 4.31 M USD |
| Cash Flow from Investing | -42.04 M USD | -28.19 M USD | -502000 USD | -10.71 M USD | 5.66 M USD | -73.13 M USD | -23.94 M USD | -6.71 M USD | -170.99 M USD | -73.85 M USD | -4.49 M USD | -5.35 M USD |
| Cash Flow from Financing | 11.28 M USD | 2.20 M USD | 865000 USD | -1.64 M USD | -12.22 M USD | 93.61 M USD | -1.49 M USD | -2.56 M USD | 143.25 M USD | 73.43 M USD | -2.81 M USD | -6.95 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | 3.41 M USD | 3.29 M USD |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | 5.59 M USD |
| Free Cash Flow | 839000 USD | 11.05 M USD | 11.39 M USD | -14.17 M USD | -15.68 M USD | 5.04 M USD | 7.75 M USD | 4.09 M USD | 4.17 M USD | 13.52 M USD | 7.95 M USD | 3.81 M USD |
Artivion Inc. is a medical device company focused on providing innovative technology solutions aimed at improving patient outcomes. Its primary function is to develop, manufacture, and sell devices associated with cardiac and vascular surgery, with a particular emphasis on cryopreservation and heart valve structures. The company's product portfolio serves critical areas such as aortic repair, heart valve therapy, and advanced cryogenic preservation techniques, underpinning its vital presence in the cardiovascular treatment sector. Its products are essential in supporting cardiac surgeons and healthcare professionals in utilizing life-saving technologies during complex medical procedures. Artivion Inc. serves a global market, impacting numerous aspects of healthcare by enabling the treatment of complex heart conditions and elevating surgical efficiency and efficacy. Headquartered in the United States, the company continues its commitment to innovation and quality in medical technology, playing a crucial role in advancing health outcomes and directly contributing to the fields of cardiovascular surgery and transplant medicine.